1938. Sustained Reduction in 30 day Readmission Rates after Implementation of an OPAT Program in an Academic Medical Center
Session: Poster Abstract Session: Clinical Practice Issues: OPAT
Saturday, October 6, 2018
Room: S Poster Hall
  • OPAT Poster IDSA 2018.pdf (262.5 kB)
  • Background: The Outpatient Parenteral Antibiotic Therapy Program at the University Of Pittsburgh Medical Center began in December 2013.  UPMC Presbyterian is a Level I center consisting of 775 beds (150 ICU beds).  Prior to program implementation, the 30-day readmission rate for patients discharged from our facility on an IV antibiotic was 32%. 

    Methods: Our Program is a multidisciplinary team consisting of physicians, advance practice providers, pharmacists, nurses, and coordinators.  We use a pharmacist based monitoring program to review weekly labs and adjust dosing through a collaborative practice agreement.  ID Fellows participate in the management of patients while receiving IV antibiotics.  Patients are evaluated one week post discharge and prior to end of therapy in the ID Clinic.  Weekly labs are monitored as per the IDSA Society Guidelines.  In addition, all patients all reviewed in our weekly huddle prior to end of therapy.  We also conduct a monthly M&M to review readmissions.

    Results: Our overall patient population has increased from 847 in 2014 to 1234 in 2015 to 1569 in 2016 and 1512 patients in 2017. Post-implementation, we have demonstrated an ongoing reduction in 30-day readmission rates.  In 2014, our rate decreased to 17.2%, in 2015 to 15.6%, in 2016 to 11.5% and in 2017 to 18.5% (see Figure 1). 2337 (54%) of patients were male; the average age of our patients was 56.4 years.  35% were diabetics; 35% have chronic kidney disease, 25.4% have CAD and 43.7% have HTN.  More patients are discharged home (n=2246) vs to a Facility (n=1583).  Over half of our patients receive vancomycin.

    Conclusion: A Pharmacist managed OPAT Program can successfully reduce and maintain lower 30 day readmission rates in an academic facility.

    Figure 1.

    Kathleen Sheridan, DO1,2, Maighdlin Anderson, DNP3, Joshua Wingfield, DNP3 and Lauren McKibben, PharmD4, (1)University of Pittsburgh, School of Medicine, Pittsburgh, PA, (2)UPMC OPAT Program, Pittsburgh, PA, (3)Department of Medicine, Division of Infectious Disease, University of Pittsburgh Medical Center, Pittsburgh, PA, (4)Infectious Disease, University of Pittsburgh Medical Center, Pittsburgh, PA


    K. Sheridan, None

    M. Anderson, None

    J. Wingfield, None

    L. McKibben, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.